In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 111 to 120 of 294

TitleTypeExpected publication date
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidanceTBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidanceTBC
Insulin efsitora alfa for treating type 2 diabetes [ID6499]Technology appraisal guidance
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Technology appraisal guidance
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]Technology appraisal guidanceTBC
Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All